These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 1313200)
1. On the mechanism of action of antiarrhythmic agents. Grant AO Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200 [TBL] [Abstract][Full Text] [Related]
2. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis. Chay TR J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110 [TBL] [Abstract][Full Text] [Related]
3. [Ion channels and arrhythmias]. Borchard U; Hafner D Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780 [TBL] [Abstract][Full Text] [Related]
4. [New aspects of the molecular effect of anti-arrhythmia agents]. Honerjäger P Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907 [TBL] [Abstract][Full Text] [Related]
5. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Whalley DW; Wendt DJ; Grant AO Pacing Clin Electrophysiol; 1995 Sep; 18(9 Pt 1):1686-704. PubMed ID: 7491312 [TBL] [Abstract][Full Text] [Related]
6. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Colatsky TJ; Follmer CH; Starmer CF Circulation; 1990 Dec; 82(6):2235-42. PubMed ID: 2242545 [TBL] [Abstract][Full Text] [Related]
7. Proarrhythmic and antiarrhythmic actions of ion channel blockers on arrhythmias in the heart: model study. Chay TR Am J Physiol; 1996 Jul; 271(1 Pt 2):H329-56. PubMed ID: 8760192 [TBL] [Abstract][Full Text] [Related]
9. [Current classification of anti-arrhythmia agents]. Weirich J; Wenzel W Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy]. Sadanaga T; Ogawa S; Okada Y; Handa S Jpn Circ J; 1992; 56 Suppl 5():1474-6. PubMed ID: 1337923 [No Abstract] [Full Text] [Related]
11. The cardiac vulnerable period and reentrant arrhythmias: targets of anti- and proarrhythmic processes. Starmer CF Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):445-54. PubMed ID: 9058848 [TBL] [Abstract][Full Text] [Related]
12. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Roden DM Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324 [TBL] [Abstract][Full Text] [Related]
13. [New aspects of the electrophysiologic effect of antiarrhythmic agents]. Antoni H; Weirich J Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893 [TBL] [Abstract][Full Text] [Related]
14. The molecular and ionic specificity of antiarrhythmic drug actions. Nattel S J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234 [TBL] [Abstract][Full Text] [Related]
15. [Potassium channels and arrhythmia]. Funck-Brentano C Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():9-13. PubMed ID: 1307198 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker. Walker MJA; Hayes ES; Saint DA; Adaikan G; Abraham S; Goldin AL; Beatch GN; MacLeod BA; Wall RA; Pugsley MK Biomed Pharmacother; 2018 Oct; 106():510-522. PubMed ID: 29990839 [TBL] [Abstract][Full Text] [Related]
17. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist. Pugsley MK; Saint DA; Hayes ES; Abraham S; Walker MJ Eur J Pharmacol; 2015 Aug; 761():330-40. PubMed ID: 26086860 [TBL] [Abstract][Full Text] [Related]
18. Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST. Campbell TJ Cardiovasc Drugs Ther; 1992 Oct; 6(5):519-28. PubMed ID: 1333276 [TBL] [Abstract][Full Text] [Related]